Subjects included in this study. Data are n (%) unless otherwise indicated.
| Characteristic | Patients with SLE, n = 50 | Entire Cohort, n = 104 |
|---|---|---|
| Male:female | 9:41 | 23:81 |
| Diagnosis | ||
| SLE | 50 | 50 (48) |
| Dermatomyositis | 11 (10.6) | |
| Mixed connective tissue disease/overlap | 10 (9.6) | |
| Sjögren syndrome | 8 (7.7) | |
| Henoch-Schönlein purpura | 7 (6.7) | |
| ANCA-associated vasculitis | 5 (4.8) | |
| Juvenile idiopathic arthritis* | 4 (3.8) | |
| Idiopathic pulmonary hemosiderosis | 3 (2.9) | |
| CNS vasculitis | 2 (1.9) | |
| Miscellaneous* | 4 (3.8) | |
| Race | ||
| White | 9 (18) | 31 (30) |
| African American | 38 (76) | 67 (64) |
| Hispanic or Latino | 2 (4) | 5 (4.8) |
| Asian | 1 (2) | 1 (1.0) |
| Age at initiation of RTX, yrs (mean ± SD) | 13.6 ± 3.5 | 12.3 ± 4.8 |
| No. RTX courses, median (range) | 2 (1–11) | 2 (1–5) |
| Duration of followup, yrs (mean ± SD) | 2.6 ± 1.5 | 2.2 ± 1.3 |
| Initial concurrent cyclophosphamide use | 28 (56) | 50 (48) |
| Patients with SLE who had nephritis, according to WHO stages | ||
| None suspected and not biopsied | 28 (56) | |
| II | 3 (6) | |
| III | 4 (8) | |
| IV | 7 (14) | |
| V | 3 (6) | |
| III/V | 5 (10) |
↵* Of the 4 patients with JIA, 1 had polyarticular JIA, 2 had systemic JIA, and 1 had enthesitis-related arthritis/inflammatory bowel disease. Of the 4 miscellaneous patients, 1 had CREST, 1 had Castleman disease, 1 had ITP, and 1 had ARRON syndrome. JIA: juvenile idiopathic arthritis; CREST: calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias; ITP: idiopathic thrombocytopenic purpura; ARRON: autoimmune-related retinopathy and optic neuropathy; SLE: systemic lupus erythematosus; ANCA: antineutrophil cytoplasmic antibodies; CNS: central nervous system; WHO: World Health Organization; RTX: rituximab.